A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group

• Published in: International journal of hematology Vol. 98; no. 2; pp. 171 - 178
• Main Authors: Torimoto, Yoshihiro, Sato, Kazuya, Ikuta, Katsuya, Hayashi, Toshiaki, Hirayama, Yasuo, Inamura, Junki, Kobayashi, Hajime, Kobayashi, Ryoji, Koda, Kyuhei, Kurosawa, Mitsutoshi, Mori, Akio, Ota, Shuichi, Sakai, Hajime, Shigematsu, Akio, Shindo, Motohiro, Shinzaki, Hitoshi, Takahashi, Fumihiko, Takimoto, Rishu, Tanaka, Junji, Yamamoto, Satoshi, Kohgo, Yutaka, Fukuhara, Takashi
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01-08-2013; Springer; Springer Nature B.V
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines - adverse effects; Asian Continental Ancestry Group; Autografts; Biological and medical sciences; Child; Disease-Free Survival; Female; Follow-Up Studies; Hematologic and hematopoietic diseases; Hematology; Humans; Japan - epidemiology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma, T-Cell, Peripheral - mortality; Lymphoma, T-Cell, Peripheral - therapy; Male; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Article; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Survival Rate; Asia; Japan; Hokkaido; Retrospective analysis; Risk factors for OS; Japanese PTCL-NOS patients; Hokkaido Hematology Study Group; Human; Hematology; Malignant hemopathy; Non Hodgkin lymphoma; Epidemiology; Peripheral T cell lymphoma; Retrospective; Lymphoproliferative syndrome; Risk factor; Cancer
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/s12185-013-1383-z

Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) comprises a group of heterogeneous lymphomas that do not fit any other identified PTCL-subgroup and show poor prognosis. To clarify clinical aspects of Japanese PTCL-NOS patients, the Hokkaido Hematology Study Group conducted a multicenter retrospective analysis. The median age of the 107 patients (male 65.4 %) was 67 years. The majority (82.4 %) had stage III/IV disease. Following the international prognostic index, 65.7 % were categorized as high intermediate or high risk. Primary chemotherapy was selected in 96 (90 %) patients, 86 of whom received anthracycline regimens. Sixteen patients received high-dose chemotherapy with autologous stem cell transplantation. Forty-eight (52 %) of the 92 evaluable patients achieved complete remission (CR) or CR/unconfirmed after the primary treatment, in which 22 (46 %) relapsed. The estimated 5-year overall survival (OS) of all patients was 35 %. Three independent risk factors (RFs) associated with OS, bulky disease (hazard ratio HR = 5.324;
p
 = 0.019), age >60 years (HR = 3.015;
p
 = 0.025), and platelet count less than 10 × 10
4
/μL (HR = 3.999;
p
 = 0.036), were identified in a multivariate analysis. Using these three RFs, the OS curves were significantly stratified into three risk groups (low risk, 0 RFs, 3-year-OS 72 %; intermediate risk, one RF, 30 %; high risk, two or three RFs, 0 %;
p
 = 0.0005). These findings may provide valuable information for the management of Japanese PTCL-NOS patients.